Eagle Pharmaceuticals Completes Acquisition Of Acacia Pharma Group Plc, Expanding Acute Care Footprint
Eagle Pharmaceuticals Completes Acquisition Of Acacia Pharma Group Plc, Expanding Acute Care Footprint
06/09/22, 11:34 AM
Location
woodcliff lakeIndustry
biotechnology
health care
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced it has completed the acquisition of the entire issued share capital of Acacia Pharma Group plc (“Acacia Pharma”) (EURONEXT: ACPH) by way of a scheme of arrangement under Part 26 of the United Kingdom’s Companies Act 2006 (the “Transaction”).
Company Info
Location
Woodcliff Lake, New Jersey, United States
Company info
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and Byfavo® and Barhemsys® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states.